Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Small Molecule Antivirals for Therapeutic Applications

Description:

Antiviral compounds that competitively disrupt virus-host interactions to inhibit disease progression and transmission 

 

Inventor

Ronald Harty

 

Problem

Hemorrhagic fever viruses such as Ebola, Marburg, and Lassa are some of the deadliest viruses in the world and yet, there are currently no vaccines or therapeutics available to control their infection and transmission. The 2014 Ebola outbreak has had devastating effects on the economies, healthcare systems and communities in the West African countries of Sierra Leone, Guinea and Liberia. This outbreak also had an impact on the U.S. economy, with $2.4 billion dollars (the most from any country worldwide) being donated in the form of personnel, technical expertise and resources to establish three new emergency operation centers to control the epidemic (CDC). While the number of hemorrhagic fever incidences has declined since 2014, a broad spectrum antiviral that is effective at controlling these viruses is urgently needed.

 

Solution

Dr. Harty and his team have identified small molecules that inhibit infectivity and spread of hemorrhagic fever viruses. These antiviral compounds disrupt key interactions between viral late (L) budding domains and mammalian host proteins. L domains are highly conserved motifs present in a wide array of RNA virus matrix proteins including filoviruses, arenaviruses, rhabdoviruses, paramyxoviruses and retroviruses, thus making these antivirals applicable to a vast assortment of human pathogens.

  

Advantages

•       Broadly applicable to viruses containing L-domains

•       Little to no risk of viruses developing resistance

•       New class of "host-oriented" therapeutics

•       Brief course of treatment

 

  

 

Stage of Development

•       In vitro studies with live virus and virus like particles are complete

•       In vitro toxicity studies are complete

•       SAR of >150 compounds completed with two lead series identified

•       Next stage is in vivo animal model studies

 

Intellectual Property

PCT Pending PCT/US2015/023502

 

Reference Media

1.       Lu et al.,  J Virol. 2014 May;88(9):4736-4743

2.       Han et al., J Virol. 2014 Jul;88(13):7294-7306

3.       Loughran et al., Bioorg Med Chem Lett. 2016 Aug 1;26(15):3429-3435 

 

Desired partnerships

• License

Co-development

 

 

Download PDF

 

Docket #  14-7018

 


Patent Information:
For Information, Contact:
Melissa Kelly
Associate Director, SEAS/SAS Licensing Group
University of Pennsylvania
215-898-9877
kellymel@upenn.edu
Inventors:
Ronald Harty
Keywords: